Search This Blog

Tuesday, October 4, 2016

Study Results Published In Journal of Clinical Oncology Show BLINCYTO® (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Results From Exploratory Pooled Phase 1 and 2 Analysis Show BLINCYTO, the Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in the U.S., Induced Complete Remission in Some Patients in all Pre-specified Subgroups
More Than Half of Patients who Achieved Complete Remission Also Experienced Complete Minimal Residual Disease Response

Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.